Table 1.
AGR3 expression and pathological features of IDC patients
| Pathological feature | No. | AGR3 expression, n (%) |
rs | p-value | |
|---|---|---|---|---|---|
| Low | High | ||||
| Age (yr) | |||||
| < 50 | 156 | 88 (56.4) | 68 (43.6) | –0.099 | 0.069 |
| ≥ 50 | 180 | 119 (66.1) | 61 (33.9) | ||
| Histological gradea) | |||||
| Ⅰ | 14 | 7 (50.0) | 7 (50.0) | –0.160 | 0.004** |
| Ⅱ | 252 | 147 (58.3) | 105 (41.7) | ||
| Ⅲ | 59 | 46 (78.0) | 13 (22.0) | ||
| Histological gradea) | |||||
| Ⅰ-Ⅱ | 266 | 154 (57.9) | 112 (42.1) | –0.159 | 0.004** |
| Ⅲ | 59 | 46 (78.0) | 13 (22.0) | ||
| Tumor size (cm)a) | |||||
| < 2 | 79 | 51 (64.6) | 28 (35.4) | 0.041 | 0.457 |
| 2-5 | 231 | 141 (61.0) | 90 (39.0) | ||
| > 5 | 23 | 13 (56.5) | 10 (43.5) | ||
| Lymph node metastases | |||||
| 0 | 122 | 75 (61.5) | 47 (38.5) | –0.007 | 0.901 |
| 1-3 | 100 | 62 (62.0) | 38 (38.0) | ||
| 4-9 | 52 | 30 (57.7) | 22 (42.3) | ||
| > 9 | 62 | 40 (64.5) | 22 (35.5) | ||
| Distant metastasis | |||||
| No | 278 | 176 (63.3) | 102 (36.7) | 0.077 | 0.161 |
| Yes | 58 | 31 (53.4) | 27 (46.6) | ||
| ER statusa) | |||||
| Negative | 123 | 102 (82.9) | 21 (17.1) | 0.336 | < 0.001 |
| Positive | 212 | 104 (49.1) | 108 (50.9) | ||
| PR statusa) | |||||
| Negative | 121 | 92 (76.0) | 29 (24.0) | 0.225 | < 0.001 |
| Positive | 214 | 114 (53.3) | 100 (46.7) | ||
| HER2 statusa) | |||||
| – to + | 265 | 157 (59.2) | 108 (40.8) | –0.098 | 0.074 |
| ++ to +++ | 69 | 49 (71.0) | 20 (29.0) | ||
| Ki-67 statusa) | |||||
| Negative | 96 | 59 (61.5) | 37 (38.5) | –0.009 | 0.874 |
| Positive | 234 | 146 (62.4) | 88 (37.6) | ||
| Recurrence or distant metastasisa) | |||||
| No | 261 | 173 (66.3) | 88 (33.7) | 0.179 | 0.001 |
| Yes | 69 | 31 (44.9) | 38 (55.1) | ||
p-value was calculated by Spearman’s rank correlation test. IDC, invasive ductal carcinoma; AGR3, anterior gradient 3; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.
**
p < 0.01.
a)
Some missing data.